1. It refers to a formula compound (IIB) or a pharmaceutically acceptable salt. Its characteristics are: R4, R5, R6, R7 and R8 can be h, halogen and thyroid； R10, R17 and R18 can be h, C1-C6 tar, cyclopentadiene c3-10； Where R17 and R18 form a C3-C7 cyclopropyl group or a non cyclopropyl group of 4-7 members together with the carbon atoms to which they attach. The most popular compounds are 7 - (2,6-fluoro-3,5-methoxybenzene) - 9-methyl-3,6,7,9-tetrahydro-8h-pyridine [4,5:5,6] pyridine-8-ona, 7 - (2,6-difluoro-3,5-dimethoxyphenyl) - 6 ', 7' - dihydrofluorine [cyclopropane-1,9 '- pyridine [2,3] - 8 (naphenyl).7 - (2,6-difluoro-3,5-dimethoxyphenyl) - 9,9-dimethyl-3,6,7,9-tetrahydro-8h-pyridine [2,3-c] - 2,7-naftiridin-8-ona. These compounds have inhibitory effects on one or more enzymes of the future generations fund and can be used to treat diseases related to the future generations fund, such as cancer.Se refiere a un compuesto de Formula (IIb) o una sal farmaceuticamente aceptable del mismo, caracterizado porque: R4, R5, R6, R7 y R8 pueden ser H, halo y metoxi； R10, R17 y R18 pueden ser H, alquilo C1-C6, cicloalquilo C3-10； donde R17 y R18 junto con el atomo de carbono al cual estan unidos forman un cicloalquilo C3-C7 o un grupo heterocicloalquilo de 4-7 miembros. Son compuestos preferidos 7-(2,6-difluoro-3,5-dimetoxifenil)-9-metil-3,6,7,9-tetrahidro-8H-imidazo[4´,5´:5,6]pirido[4,3-d]pirimidin-8-ona； 7´-(2,6-difluoro-3,5-dimetoxifenil)-6´,7´-dihidroespiro[ciclopropano-1,9´-pirido[2,3-c][2,7]naftiridin]-8´(3´H)-ona； 7-(2,6-difluoro-3,5-dimetoxifenil)-9,9-dimetil-3,6,7,9-tetrahidro-8H-pirrolo[2,3-c]-2,7-naftiridin-8-ona. Dichos compuestos son inhibidores de una o mas enzimas del FGFR y son utiles en el tratamiento de enfermedades asociadas con FGFR tales como el cancer.
